EGFR and cancer: MiR-146b-5p suppresses interleukin-1 receptor-associated kinase 1 expression, thereby inhibiting NF-κB activity and subsequent production of NF-κB-associated IL-6 and IL-8 in two primary EGFR T790M-preserved osimertinib-resistant cancer cell lines, PE2988 and PE3479, and enhanced EGFR TKI-induced apoptosis (40).